REFERENCES
MacDermott RP, Stenson WF: Alterations of the immune system in ulcerative colitis and Crohn's disease. Adv Immunol 42:285–328, 1988
McCarthy DA, Rampton DS, Liu Y-C: Peripheral blood neutrophils in inflammatory bowel disease. Morphological evidence of in vivo activation in active disease. Clin Exp Immunol 86:489–493, 1991
Claudio Fiocchi: Inflammatory bowel diseae: etiology and pathogenesis. Gastroenterology 115:182–205, 1998
Truelove SC, Jewell DP: Intensive intravenous regimens for severe attacks of ulcerative colitis. Lancet 1:1067–1070, 1974
Allison MC, Dhillon AP, Lewis WG, Pounder RE (eds): Inflammatory Bowel Disease. London, Mosby, 1998
Jarnerot G, Rolny P, Sandberg-Gertzen H: Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89:1005–1013, 1985
Cassatella MA: The production of cytokines by polymorphonuclear neutrophils. Immunol Today 16:21–26, 1995
Grisham M.B., Yamada T: Neutrophils, nitrogen oxides and inflammatory bowel disease, neuro-immuno-physiology of the gastrointertinal mucosa. Ann NY Acad Sci 664:103–115, 1992
Roseth AG, Schmidt PN, Fagerhol MK: Correlation between faecal excretion of Indium-111-labelled granulocytes and calprotectin, a granulocyte marker. Scand J Gastroenterol 34:50–54, 1999
Limburg PJ, David MPH, Ahlquist A, Sandborn WJ, Mahoney DW, Devens ME, et al: Faecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhoea referred for colonoscopy. Am J Gastroenterol 95:2831–2837, 2000
Tibble JA, Sigthorsson G, Bridger D, Fagerhol MK, Bjarnason I: Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119:15–22, 2000
Rachmilewitz D (on behalf of an international study group): Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis. Br Med J 298:82–86, 1989
Sandborn WJ, Tremaine WJ, Schroeder KW, Steiner BL, Lawson GM: Cyclosporine enemas for treatment-resistant, mildly to moderately active left-sided ulcerative colitis. Am J Gastroenterol 88:640–645, 1993
Ohara M, Saniabadi AR, Hirata I, Adachi M, Agishi T, Kasukawa R: Granulocytapheresis in the treatment of patients with rheumatoid arthritis. Artif Organs 21:989–994, 1997
Kashiwagi N, Hirata I, Kasukawa R: A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 2:134–141, 1998
DeForge L, Kenney JS, Jones ML, Warren JS, Remick DG: Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. J Immunol 148:2133–2141, 1992
Saverymuttu SH: Clinical remission in Crohn's disease: assessment using faecal 111In granulocyte excretion. Digestion 33:74–79, 1986
Edwards SW, Hallet MB: Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 18:320–324, 1997
Sandborn WJ: A critical review of cyclosporin therapy in in-flammatory bowel disease. Inflamm Bowel Dis 1:48–63, 1995
Present DH: Infliximab therapy for ulcerative colitis: many unanswered questions. Am J Gastroenterol 96:2294–2296, 2001
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hanai, H., Watanabe, F., Saniabadi, A.R. et al. CASE REPORT: Therapeutic Efficacy of Granulocyte and Monocyte Adsorption Apheresis in Severe Active Ulcerative Colitis. Dig Dis Sci 47, 2349–2353 (2002). https://doi.org/10.1023/A:1020159932758
Issue Date:
DOI: https://doi.org/10.1023/A:1020159932758